HMGB1 inhibitors(High Mobility Group Protein B1 inhibitors), HMGB2 inhibitors(high mobility group box 2 inhibitors), KEAP1 inhibitors(Kelch-like ECH-associated protein 1 inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Parkinson DiseaseEpilepsyNeuroinflammation

Inactive Indication-

Originator Organization

Seoul National University

Active Organization

Zhejiang University

Seoul National University

Sparkbiopharma Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC21H19N3O4

InChIKeyVVOXDJYPDCSQMI-UHFFFAOYSA-N

CAS Registry908568-01-4

100 Clinical Results associated with Inflachromene

100 Translational Medicine associated with Inflachromene

100 Patents (Medical) associated with Inflachromene

211

Literatures (Medical) associated with Inflachromene

01 Sep 2025·Journal of Pharmaceutical and Biomedical Analysis

Simultaneous determination of three iodinated contrast media in human plasma by LC/MS-MS and its clinical application

Article

Author: Cai, Jianfang ; Wang, Hongyun ; Wu, Xiaofei ; Wang, Yaoyao ; Liu, Shupeng

Iodinated contrast media (ICM), including iohexol, iopromide and iodixanol, have significantly enhanced diagnostic accuracy, particularly in cardiovascular and cerebrovascular diseases. The three ICM is tailored to specific patient needs and diagnostic contexts. However, excessive doses of ICM may induce adverse reactions, including nephrotoxicity. Accurate measurement of ICM concentration is essential for reducing renal burden and ensuring patient safety. Current methods for quantifying ICM are often limited to single-analyte detection (especially iohexol), which is inefficient for clinical practice. Therefore, this method aims to develop and validate a rapid, generic LC-MS/MS method for simultaneously quantifying iohexol, iopromide, and iodixanol in human plasma to improve patient management and prognosis. An LC-MS/MS-based approach was established utilizing an C18 column coupled with a Xevo TQ-S triple quadrupole mass spectrometer. Sample preparation involved protein precipitation, while chromatographic separation was achieved using acetonitrile and 0.1 % formic acid in water. The developed LC-MS/MS method achieved satisfactory separation of the three ICM within 1.5 min. Calibration curves for iohexol, iopromide, and iodixanol showed good linearity in 5.00-5000, 5.00-5000 and 10.0 ∼ 10000 µg/mL, respectively. The method was effectively applied to analyze 71 plasma samples from 9 patients, highlighting its clinical utility. A rapid and generic LC-MS/MS method streamlines sample preparation and standardizes laboratory workflows, making it suitable for clinical bio-samples.

13 Mar 2025·The Journal of Physical Chemistry B

Exploring the Adsorption Process of Iodinated Contrast Medias onto Phospholipid Membranes: A Theoretical Toxicity Evaluation Study

Article

Author: Xie, Song ; Liu, Wei ; Xu, Jing ; Zhu, Hao ; Gao, Jinsong ; Xu, Fengjing ; Li, Jinlong ; Liu, Yichang ; Wang, Liangjie

Iodinated contrast media (ICM) molecules are widely used in medical diagnostic imaging. With the increasing consumption of ICM, these compounds have been identified in groundwater and surface water systems. However, the effect of these environmental pollutants on living organisms remains inadequately studied. Herein, we employed molecular dynamics (MD) simulations to investigate the interactions between ICM molecules and the cell membranes. Our findings indicated that the entry behavior of ICM molecules into the membrane is dependent on their chemical structure. The insertion of ICM molecules affects the alignment of phospholipid headgroups and the order parameters of phospholipid tails, resulting in membrane thickness fluctuations. In addition, we observed that the distribution of ICM molecules in the membrane was related to the type of phospholipid. The proportions of phospholipids around the ICM molecules were different. Furthermore, the potential of mean force revealed that different ICM molecules had distinct free energy change characteristics when they transport from an aqueous environment to the membrane center. Some ICM molecules could access the membrane center after overcoming a small energy barrier, suggesting their potential transmembrane ability. This work systematically studied the effects of ICM on cell membranes, providing theoretical evidence for the environmental hazards of ICM.

01 Mar 2025·Clinical Radiology

Adverse reactions to iodinated contrast media in patients with a history of allergies

Article

Author: Li, J ; Xiong, K ; Liu, H ; Li, X ; Lan, F ; Zhao, L ; Zhang, J ; Liu, J

OBJECTIVETo investigate the prevalence, patterns and influence factors for iodinated contrast media (ICM)-related adverse reaction (AR) in patients with a history of allergies.METHODSPatients with a history of allergies who underwent contrast-enhanced CT between January 2014 and December 2020 were enrolled. ICM-related AR and patient information were retrospectively analyzed. χ² and Student t test were used to compare between different groups, and logistic regression analyses were adopted to investigate influence factors for AR.RESULTS325243 patients performed contrast-enhanced CT examinations. 713 cases with ICM allergy history and 27045 cases with non-ICM allergies history were included. The overall AR incidence was 0.66% (184/27758) and severe AR occurred in 0.05% (14 of 27758). 90.22% (166/184) of AR occurred within 20 minutes after injection. 2 severe AR occurred more than 30 minutes in patients with non-ICM allergies history. Compared with other ICMs, iodixanol was associated with higher incidence of AR in patients with ICM allergy history (10.71%; 12 of 112) and non-ICM allergies history (1.1%; 46 of 4172). Iohexol was associated with lower incidence of AR in patients with non-ICM allergies history (0.24%; 17 of 7134). Age ≥70 years (OR, 0.2; P<0.001) and hypertension (OR, 0.6; P=0.025) were protective factors for ICM-related AR in patients with non-ICM allergies history.CONCLUSIONSIn patients with a history of allergies, most AR occurred within 20 minutes after injection. The AR incidence was associated with ICM generics. Age ≥70 years and hypertension were protective factors for ICM-related AR in patients with non-ICM allergies history.

100 Deals associated with Inflachromene

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Preclinical	South Korea	Sparkbiopharma Co., Ltd.	01 Jan 2024
Parkinson Disease	Preclinical	South Korea	Seoul National University	01 Jan 2024
Epilepsy	Preclinical	South Korea	Seoul National University	19 Apr 2023
Epilepsy	Preclinical	China	Zhejiang University	19 Apr 2023
Neuroinflammation	Preclinical	South Korea	Seoul National University	12 Oct 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Inflachromene

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation